SIGNPATH PHARMA, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-09-11: Form 8-K; Period of report 2015-09-04; Description 8.01 Other Events; Details 8.01.
- 2015-05-01: Form 8-K; Period of report 2015-05-01; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2015-02-13: Form 8-K; Period of report 2015-02-11; Description 4.01 Changes in Registrant's Certifying Accountant; Details 4.01.
- 2015-02-02: Form 8-K; Period of report 2015-01-27; Description 4.01 Changes in Registrant's Certifying Accountant; Details 4.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-09-11 | 8-K | 2015-09-04 | 8.01 Other Events | 8.01 In an action by consent on September 4, 2015, a majority of the shareholders of SignPath Pharma, Inc. (the “Company”) approved an increase in the number of shares and options available under the Company’s 2009 Employee Stock Incentive Plan (the “Plan”). | signpath_8k.htm |
| 2015-05-01 | 8-K | 2015-05-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective May 1, 2015, Kai Larson was appointed Vice President of Corporate Development, Chief Operating Officer, and Secretary of SignPath Pharma Inc. (the “Company”). | signpath.htm |
| 2015-02-13 | 8-K | 2015-02-11 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On February 11, 2015, SignPath Phama Inc., a Delaware corporation (the “Company”) engaged Friedman LLP (“Friedman”) as the Company’s new Independent Certified Public Accountants. | signpath8k.htm |
| 2015-02-02 | 8-K | 2015-01-27 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On January 27, 2015, the Board of Directors (the “Board”) and the Audit Committee of the Board (the “Audit Committee”) of SignPath Phama Inc., a Delaware corporation (the “Company”), approved the termination of M&K CPAS, PLLC (“M&K”) as the Company’s Independent Certified Public Accountants for the Company’s fiscal year ended December 31, 2014. | signpath.htm |
| 2014-06-09 | 8-K | 2014-06-03 | 8.01 Other Events | 8.01 On June 3, 2014, SignPath Pharma Inc. issued a press release titled “SignPath Pharma Announces IND Approval of Liposomal Curcumin for Clinical Trials of Drug Resistant Non-Small Cell Lung Cancer and Progressive Parkinson’s Disease” (the “Press Release”). | signpath.htm |
| 2012-08-15 | 8-K | 2012-08-14 | 9.01 Financial Statements and Exhibits | signpath8k20120814.htm | |
| 2011-10-21 | 8-K | 2011-10-20 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On October 20, 2011, SignPath Pharma Inc. (the “Company”) filed a certificate of amendment (the “Certificate”) with the Secretary of State of Delaware increasing the authorized capital stock of the Company to 55,000,000 shares, consisting of (i) 50,000,000 shares of Common Stock, par value $.001 per share; and (ii) designating 5,000,000 shares of Preferred Stock, par value $.10 per share. | signpathpharma.htm |
| 2010-08-23 | 8-K | 2010-08-02 | 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | 4.02 On or about August 2, 2010, SignPath Pharma Inc.’s (the “Company”) management and Board of Directors were advised by its auditor of record, M&K CPAS, PLLC (“M&K”), that the Company’s financial statements contained within the Company’s 10-K for the year ended December 31, 2009 and 10-Qs for the quarters ended March 31, 2009, June 30, 2009, September 30, 2009, and March 31, 2010, contain misstatements regarding our classification of preferred stock and related warrants as derivative liabilities and that such previously filed quarterly and yearly financial statements should no longer be relied upon, as previously presented. | v194882_8k.htm |
| 2010-07-15 | 8-K | 2010-07-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (e) Effective July 12, 2010, SignPath Pharma (the “Company”) elected Jack Levine to its Board of Directors. | v190697_8k.htm |
| 2009-11-12 | 8-K/A | 2009-10-02 | 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | 4.02 (b) the prospectus filed under Rule 424(b)(3) filed with the Commission on August 11, 2009 (the “Final Prospectus”, with the “Form S-1/A, the “Filings”). | v165152_8ka.htm |
| 2009-10-05 | 8-K | 2009-10-02 | 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | v162108_8k.htm | |
| 2009-09-29 | 8-K/A | 2009-08-10 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 (a) Effective as of August 10, 2009, upon the authorization and approval of its Board of Directors, SignPath Pharma Inc., a Delaware corporation (“Registrant”) dismissed Moore & Associates Chartered (“Moore & Associates”) as its independent registered public accounting firm. | v161549_8ka.htm |
| 2009-09-02 | 8-K/A | 2009-08-10 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 (a) On August 13, 2009, SignPath Phama Inc. (the “Registrant”) filed a Current Report on Form 8-K to disclose that it had replaced Moore & Associates (“Moore & Associates”) as its independent registered public accounting firm. | v159649_8ka.htm |
| 2009-08-13 | 8-K | 2009-08-10 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 (a) Effective as of August 10, 2009, upon the authorization and approval of its Board of Directors, SignPath Pharma Inc., a Delaware corporation (“Registrant”) replaced Moore & Associates Chartered (“Moore & Associates”) as its independent registered public accounting firm. | v157580_8k.htm |